Fly News Breaks for February 3, 2020
NVS, AGN, EYEN
Feb 3, 2020 | 07:22 EDT
Oppenheimer analyst Esther Rajavelu downgraded Eyenovia (EYEN) to Perform from Outperform on competitive considerations. The analyst notes that competitive pipelines in development include Allergan's (AGN) Presbysol and Novartis' (NVS) UNR844-Cl.
News For EYEN;AGN;NVS From the Last 2 Days
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.